G A Engler

Learn More
Acute myeloid leukemia (AML) patients with DNA methyl-transferase 3A (DNMT3A) mutations in remission after induction chemotherapy may have hematopoiesis arising from a putative pre-leukemic clone lacking the full spectrum of mutations seen at AML diagnosis. 1,2 DNMT3A mutations in hematopoietic stem cells lead to increased self-renewal capacity and(More)
  • 1